Tower Research Capital LLC TRC grew its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 816.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 63,458 shares of the company's stock after purchasing an additional 56,534 shares during the period. Tower Research Capital LLC TRC's holdings in Roivant Sciences were worth $751,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Treasurer of the State of North Carolina raised its stake in Roivant Sciences by 0.6% during the fourth quarter. Treasurer of the State of North Carolina now owns 187,047 shares of the company's stock worth $2,213,000 after acquiring an additional 1,170 shares during the period. GAMMA Investing LLC raised its position in shares of Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after purchasing an additional 1,288 shares during the period. WINTON GROUP Ltd lifted its holdings in shares of Roivant Sciences by 1.5% in the 4th quarter. WINTON GROUP Ltd now owns 92,526 shares of the company's stock worth $1,095,000 after purchasing an additional 1,332 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Roivant Sciences by 7.5% in the 4th quarter. Covestor Ltd now owns 20,634 shares of the company's stock worth $245,000 after purchasing an additional 1,444 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after purchasing an additional 1,507 shares during the period. 64.76% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several equities research analysts have weighed in on ROIV shares. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Monday, April 21st. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.
Read Our Latest Analysis on Roivant Sciences
Insider Transactions at Roivant Sciences
In other news, COO Eric Venker sold 218,041 shares of the company's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.42, for a total value of $2,271,987.22. Following the completion of the sale, the chief operating officer now owns 896,869 shares in the company, valued at $9,345,374.98. This represents a 19.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the transaction, the chief accounting officer now directly owns 163,264 shares in the company, valued at approximately $1,702,843.52. The trade was a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,395,541 shares of company stock valued at $14,922,538. Company insiders own 7.90% of the company's stock.
Roivant Sciences Price Performance
ROIV opened at $11.01 on Friday. The stock's 50 day moving average price is $10.34 and its 200 day moving average price is $11.15. The stock has a market cap of $7.86 billion, a P/E ratio of -73.40 and a beta of 1.25. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Equities analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current year.
Roivant Sciences Company Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
